Skip to main content
Caplight Logo









DR. VIVIEN KARL

DR. VIVIEN KARL

Private
BerlinConsumer & Commercehttps://drvivienkarl.com/

Last Round

Pre Seed

May 9, 2023

Total Funding Raised

$1.63M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

DR. VIVIEN KARL is a personal products company that develops and sells natural, science-based intimate care products for women.

Sector

Consumer & Commerce

Verticals

D2C Brands, Fashion & Beauty, E-commerce

Business Model

B2C

Customer Profile

Hardware Sales, Hardware + Subscription

AI Layer

Non-AI

Keywords

intimate careD2C brandfemtechintimate drynessmenopause carewomen's healthnatural skincareat-home health testsubscription modelfounder-led brandpharmacy distribution

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

DR. VIVIEN KARL Comparables

Compare DR. VIVIEN KARL with similar companies based on industry and business-model similarity.

DR. VIVIEN KARL comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
DR. KADE Pharmazeutische Fabrik
74%
Combe
67%
Compass Diversified Holdings
65%

DR. VIVIEN KARL Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre SeedMay 9, 2023
Pre SeedAug 18, 2022

Key People

Founding team and executive leadership

Vivien Karl

CEO & Co-Founder

Founding Team

DR. VIVIEN KARL Investors

Notable investors and investment history

DR. VIVIEN KARL investors
InvestorRounds
better venturesPre Seed
Dieter von Holtzbrinck VenturesPre Seed
Leanox Impact CapitalPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 17, 2026

    Open roles increased to 6, 2.5x the trailing average.

  • Aug 3, 2026

    Open roles increased to 4, 29% of headcount.

DR. VIVIEN KARL Filings

Explore SEC and related filing metadata, where available.

DR. VIVIEN KARL filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about DR. VIVIEN KARL's valuation, stock price, and market status.

Is DR. VIVIEN KARL a public or private company?

DR. VIVIEN KARL is a private company.

What is the current stock price of DR. VIVIEN KARL?

DR. VIVIEN KARL is a private company with no public stock price. No recent secondary market data is available.

How much is DR. VIVIEN KARL worth (valuation)?

Valuation information for DR. VIVIEN KARL is not publicly available.

Can I buy DR. VIVIEN KARL stock?

DR. VIVIEN KARL shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was DR. VIVIEN KARL's last funding round?

DR. VIVIEN KARL's most recent funding round was Pre Seed on May 9, 2023.

Who are the main investors in DR. VIVIEN KARL?

Key investors in DR. VIVIEN KARL include Dieter von Holtzbrinck Ventures.

Will DR. VIVIEN KARL IPO soon?

No public IPO plans have been announced for DR. VIVIEN KARL.

How can I track DR. VIVIEN KARL secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor DR. VIVIEN KARL's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBerlin
Employee Range14
Year Founded2021
Last FundingMay 9, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?